Prescription drugs Food & health See all topics Facebook Tweet Email Link Link Copied! Follow

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat diabetes.

Lilly says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of day.

The study of more than 3,127 ad

See Full Page